Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory WHO Grade 2 Glioma”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Testing effectiveness (Phase 2)Study completedNCT01866449
What this trial is testing

Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme

Who this might be right for
Glioblastoma Multiforme (GBM) WHO Grade IV
University of Ulm 24
Post-approval studies (Phase 4)Ended earlyNCT04650204
What this trial is testing

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

Who this might be right for
Intractable EpilepsyMalignant GliomaSeizure Disorder+2 more
Mayo Clinic 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT04284774
What this trial is testing

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Who this might be right for
Malignant Solid NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent Ectomesenchymoma+38 more
National Cancer Institute (NCI) 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT04320888
What this trial is testing

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Who this might be right for
Hematopoietic and Lymphatic System NeoplasmRecurrent EpendymomaRecurrent Ewing Sarcoma+35 more
National Cancer Institute (NCI) 1
Large-scale testing (Phase 3)Active Not RecruitingNCT04576117
What this trial is testing

Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Who this might be right for
Recurrent Low Grade AstrocytomaRecurrent WHO Grade 2 GliomaRefractory Low Grade Astrocytoma+2 more
National Cancer Institute (NCI) 300
Early research (Phase 1)Study completedNCT03434262
What this trial is testing

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Who this might be right for
Anaplastic AstrocytomaAnaplastic EpendymomaAnaplastic Ganglioglioma+53 more
St. Jude Children's Research Hospital 68
Early research (Phase 1)Active Not RecruitingNCT02208362
What this trial is testing

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

Who this might be right for
Recurrent GlioblastomaRecurrent Malignant GliomaRecurrent WHO Grade II Glioma+5 more
City of Hope Medical Center 65
Testing effectiveness (Phase 2)Active Not RecruitingNCT04195555
What this trial is testing

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Recurrent EpendymomaRecurrent Ewing SarcomaRecurrent Hepatoblastoma+30 more
National Cancer Institute (NCI) 3